🇺🇸 FDA
Pipeline program

AMX0035, PL1 Oral powder in sachet, oral use

A35-004

Phase 3 small_molecule active

Quick answer

AMX0035, PL1 Oral powder in sachet, oral use for Amyotrophic Lateral Sclerosis (ALS) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials